Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Adenovirus Vector COVID-19 Vaccines for Radiotherapy Patients in Thailand
TCTR20210921002Recruiting
- Sponsor
- King Chulalongkorn Memorial Hospital
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of adenovirus vector COVID-19 vaccine in coronavirus disease 2019 (COVID-19), sponsored by King Chulalongkorn Memorial Hospital. Primary endpoints: Safety of adenovirus vector COVID-19 vaccines and Immunogenicity of adenovirus vector COVID-19 vaccines. Started Sep 2021; status: recruiting.
02
Drugs
adenovirus vector COVID-19 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20210921002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210921002.